We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+31.01%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$570M
AUM Growth
+$85.9M
Cap. Flow
-$10.1M
Cap. Flow %
-1.78%
Top 10 Hldgs %
79.11%
Holding
57
New
1
Increased
2
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$46.1M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$2.79M
3
CYPH
Cypherpunk Technologies Inc
CYPH
+$2.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.4M
2
ACLX
Arcellx
ACLX
+$11.3M
3
VRNA
Verona Pharma
VRNA
+$7.41M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$6.52M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$198M 34.81%
5,161,888
– –
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.35B
$77.1M 13.52%
4,519,361
– –
SLRN
3
DELISTED
ACELYRIN
SLRN
$47.2M 8.28%
+2,256,022
New +$46.1M
SRRK icon
4
Scholar Rock
SRRK
$5.71B
$34.7M 6.09%
4,598,828
– –
LENZ
5
LENZ Therapeutics
LENZ
$172M
$22M 3.86%
1,208,473
– –
ACLX
6
DELISTED
Arcellx
ACLX
$19.4M 3.41%
613,921
-295,658
-33% -$11.3M
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$15.9M 2.8%
967,527
-441,882
-31% -$5.74M
ZYME icon
8
Zymeworks
ZYME
$1.68B
$12.6M 2.21%
1,458,875
-161,812
-10% -$1.45M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.1M 2.13%
308,151
-378,684
-55% -$13.4M
LYRA
10
DELISTED
LYRA THERAPEUTICS INC
LYRA
$11.4M 2.01%
55,605
+20,060
+56% +$2.79M
HLVX
11
DELISTED
HilleVax
HLVX
$10.3M 1.81%
599,274
-10,588
-2% -$164K
DICE
12
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$9.42M 1.65%
202,773
– –
STRO icon
13
Sutro Biopharma
STRO
$379M
$7.79M 1.37%
167,558
– –
VRNA
14
DELISTED
Verona Pharma
VRNA
$7.35M 1.29%
347,500
-347,501
-50% -$7.41M
ACRS icon
15
Aclaris Therapeutics
ACRS
$730M
$7.22M 1.27%
696,171
– –
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.09M 1.24%
640,688
– –
PRME icon
17
Prime Medicine
PRME
$533M
$6.89M 1.21%
470,304
– –
NKTX icon
18
Nkarta
NKTX
$162M
$6.28M 1.1%
2,868,035
– –
PEPG icon
19
PepGen
PEPG
$133M
$5.82M 1.02%
651,050
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7B
$5.69M 1%
345,293
– –
IMCR icon
21
Immunocore
IMCR
$1.78B
$4.85M 0.85%
80,963
– –
IMTX icon
22
Immatics
IMTX
$1.24B
$4.57M 0.8%
396,000
-99,000
-20% -$924K
JANX icon
23
Janux Therapeutics
JANX
$935M
$4.28M 0.75%
360,414
– –
EYPT icon
24
EyePoint Inc
EYPT
$1.02B
$3.76M 0.66%
432,000
-48,000
-10% -$293K
DBTX
25
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$3.09M 0.54%
801,629
– –
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2023 Portfolio in Review

As of Q2 2023, Samsara BioCapital held 57 positions worth $570M, up 18% from $484M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Samsara BioCapital's Q2 2023 filing shows 1 new, 2 increased, 9 reduced and 10 closed positions. Its largest new stake was ACELYRIN: 2,256,022 shares worth $47.2M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Samsara BioCapital's largest Q2 2023 buy was ACELYRIN: 2,256,022 shares worth $47.2M.
  • Samsara BioCapital added most to LYRA THERAPEUTICS INC in Q2 2023, an estimated $2.79M increase.
  • Samsara BioCapital's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $13.4M.
  • Samsara BioCapital fully exited Centessa Pharmaceuticals in Q2 2023, selling an estimated $6.52M.
  • Samsara BioCapital's ten largest holdings make up 79% of its $570M portfolio in Q2 2023.
  • Samsara BioCapital opened 1 new position and closed 10 in Q2 2023.
  • Samsara BioCapital's portfolio value rose 18% quarter-over-quarter to $570M.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.